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Abstract: A dysprothrombindesignatedprothrombinSegoviawas isolatedfrom the plasmaof an
individualwithnormalprothrombinantigenandprothrombinactivitylesserthan25°Aof the
controlprothrombinactivity.Activationby prothrombinasecomplex showed a lower
amidolyticthanclottingactivity,whichsuggestsa lessergenerationof activeintermediates
thannormalprothrombin.WhenprothrombinSegoviawas activatedby protbrombinase
complexm the absenceof iktor Va, no tbrombinformationwas foundby fictional
activities.SDS-PAGEanalysisof themoleculesderivedby activationwithprotbrombrnase
comple> Taipansnakevenom andEchis carinafusvenom showedan accumulationof
moleculesnot cleavedatbondArg320-lle321.Ihis wasmoreevidentwithEchiscarinutus
veno~ whichonlyactson thisbond.Ourdatasuggesthatthealterationof prothrombin
Segoviaimpairsthescissionof bondArg320-Ile321.
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Dysprothrombinemiasrepresentoneof themostuncommoncoagulationdefects;so fir, 21variantsjall
of them charactetid by a decreasem the fictional level of prothrombincomparedto the
immunologicallydetectableprothrombin(l), havebeenreported(2-7).
The conversionof humanprothrombinto thrombrnrequirestwo cleavages(8): one at bond A
(Arg271-Thr272),thatsplitsprothrombinrntofragment1+2 (F1+2) andprethrombin2 (P2), and
anotheratbondB (Arg320-lle321),whichexposestheactivesite(9) andyieldsthedisulfide-linked
two-chain(A andB chains)enzymethrombin.Thesecleavagescanbeproducedmtheoppositeorder,
yieldingfirst the disulfiddinkedtwo-chainactiveintermediatemeizothrombin(MT), and thq
tbrombin.Thereare alsotwo morepeptidebondssusceptibleto autocatalysis;bond C (Arg155-
Ser156),andbondD, (Arg286-Thr287).Cleavageof bondC fromprothrombinproducesprethrombin
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1(PI), andfromMT producesmeizothrombin-desFl(MT-desFl),anotherdisulfideIiukedtwo chain
activeintermediate(10, 11).
Elevenof the prothrombrnvariantshave been purKedand characterized(2, 12). Prothrombrns
Barcelonaand MMM4 have a iinwtionaldefectafFectingbond A; prothrombinClamarthas a
finwtionaldefecttiecting bondB; prothrombinSanJuanis thoughto havea calciumbindingdefect,
andfinally,anabnormalityof thethrombinactivesitehasbeendemonstratedfor prothrombrnsMolise,
Quick,Metq %lakta,Tokushima,Habana ndHimi(2, 7, 13,14).
The speciticmoleculardefect has been identifiedas a single amino-acidsubstitutionm the
dysprothrombinemiasBarcelona ndMadrid(Arg271+Cys)(15, 16),Tokushima(Arg418-+Trp)(17,
18)and%lakta(Giu466-+Ala)(19) andas a doubleamino-acidsubstitutionm protrombrnsQuick
(Arg382+Cys andGly588+Val) (20, 21) andHimi(Met337+ThrandArg388+His) (22), which
arethetwo uniquecasesknownto be compoundsheterozygousfor two dysfimctionalprothrombin
molecules.
ProthrombinSegovia(l), characterizedby abnormallylow levelsof plasmaprothrombrnactivityusing
bothphysiologicactivatorsaswellasRusse~NotechisscutatusorEchiscarinatusvenoms,showeda
more cathodicmobilitym plasmaimmunoelectrophoresisthannormalprothrombin,andhadin the




Blood was collectedfrom the probandusingplasticsyringesthatcontained1/10 (v:v) of 3.8Y0
trisodiumcitrate.Platelet-poorplasmawasobtainedtier centrifhgationat2500g for 30 minutesat
4°C andstoreda-80”C.
Prothrombrnobtainedfromthealreadyrefined(1) heterozygouspatientandnam~ for theremaining
of this manuscript,as prothrombinSegovia,was isolatedby barimncitrateadsortionlelution,
ammoniumsulphateprecipitation(23) andDEAESephadex(Pharmacia)chromatography(24). Itwas
thenstudiedby immunoelectrophoresisperformedaccordingto Scheidggeret al (25), bidimensional






Thrombinclottingactivitywas determinedby its abilityto clot humanpuri6edfibrinogen(Kabi-
Vitrum),usinghumanthrombrn(Roche)forthecalibrationcurve.Amidolyticactivityof thrombinand
thrombin-likenzymeswas determined by followingspectrophotometsicallythe hydrolysisof the
chromogenicsubstrateS-2238(H-D-Phe-Pip-Arg-pNA)(Kabi-Vitrnm)at405(29).
Prothrombinactivationproductswere identifiedby SDS-PAGEwith and withoutdithiothreithol
(DTT),m orderto identi@thefollowingmolecules:prothrombinandMT (72000),P1 andMT-desFl
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(57000) and P2 and thrombrn(38000). When Echis carinatusvenom was used as activator,
prothrombrnactivationproductswereanalymdby Westernblot(30, 31). Determinationof F1+2was
performedaccordingto the methodof Pelzer(32) usinga commerciallyavailableimmunoassay
(Behring).
Theincubation*es werethefollowing:
a. Prothrombrnasecomplex:prothrombrn(4.2-8.4~ghnl)wasincubatedwithfiwtorXa (0.02 U/ml),
factorV (0.012U/ml)andrabbitbraincephalin(1:5 v/v) m 0.1 M Tris,0.1 M NaC~0.01M CaClz,
pH=7.4.Inabsenceof fktor V, the concentrationoffktor Xa was2 U/ml.In SDS-PAGEandF1+2
deterroinatio~prothrombrn(25 pghnl)was incubatedwithfhctorXa (0.35 U/ml), fiwtorV (0.024
U/ml)andrabbitbraincephalin(1:3.5v/v) in0.1M Tris,0.1M NaC~0.04M CaClz,pH=7.4.
b. Taipansnakevenom:prothrombrn(2.1-4.2pghnl)wasincubatedwiththevenom(0.2 pghnl)and
rabbitbraincephalin(1:10v/v) m 0.05M Tris,0.1 M NaC~0.01M CaC12,pH=7.4.In SDS-PAGE
andF1+2determinatio~prothrombrn(50 pghnl)wasincubatedwiththevenom(16 ~ghnl)andrabbit
braincephalin(1:9v/v) in0.05M Tris,0.1M NaC~0.04M CaClz,pH=7.4.
c. Echiscarinamsvenom prothrombrn(4.2-8.4pghnl)wasincubatedwiththevenom(2.5 pghrd)in
0.02M Tris,0.1 M NaC~pH=7.4.In SDS-PAGEandF1+2determinatio%prothrombin(60 pghnl)
wasincubatedwiththevenom(35 pghd) intheabovebu.iler.
RESULTS
Afler theadsorptionof propositu’splasmaonto bariumcitrateandthe eliminationof mostplasma
proteins,two peakswereobtainedfromtheDEAE-Sephadexcolumn.Thesecondof themcontaining
prothrombinSegovia,similaryto normalprothrombin,elutedatthesameionicstrength,migratedasa
singleband,hadthe samemobilitym SDS-PAGEanditsmolecularweightwas estimatedas 72000
(fig. 1).Nevertheless,theimmunoeleetrophoreticmobilityof thisprothrombrnwasmorecathodicthan
thatof normalprothrombrn,alreadycon6rmedbybidimensionale eetrophoresis.
Activationof the propositu’spurifiedprothrombrn,(prothrombrnSegovia),by the prothrombrnase
complexshoweda delayofthrombrnproduction,determinedby clottingaswellasamidolyticactivity
(fig.2). ThethrombrnactivitygeneratedbyprothrombinSegoviawas85% of thenormalactivityupon
fibrinogenand 35% upon syntheticsubstrateS-2238.However,simikuyto normalprothromb~
prothrombrnSegoviareachedmaximumamidolyticactivityfhsterthanmaximumclottingactivity.
Whenthe activationwas carriedout in absenceof fhctorVa, no clottingactivityappearedfrom
prothrombinSegoviaandamidolyticactivityreachedaplateauatlessthan5% of thenormalmaximum
activity(fig. 2). Therateof F1+2productionby prothrombrnSegoviawas similarto thatof normal
prothrombin(fig. 3a). Althoughthe cleavagepatternof both prothrombinson SDS-PAGE was
similar,the appearanceof 57,000(Pl or MT-desF-1)and38,000Da (P2 or thrombrn)fragments
occurredlaterinprothrombinSegovia.DTTreductionhadamoreintensiveffectontheactivationof
normalprothrombrnfragmentsproducrngB ch@ whileon prothrombinSegovia,onlya decreaseof
intensityof thefragmentswasseen(datanonshown).
AfleractivationwithTaipansnakevenorq Segovia’andnormalprothrombrnsreachedclottingand
amidolyticactivityplateausatthesametime(45 and20 minutesrespectively)(fig. 4) buttheformer
generated367. and42.8Y0of clottingandamidolyticactivitymrelationto thelatter.F1+2production
was similarto thatof normalprothrombtiandgreaterthanwiththe rest of activators(fig. 3b).
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the productionof thrombrnfromprothrombinSegovia,measuredby clottingas well as amidolytic
activity,was lessthanS’%o of theproducedby normalprothrombin,evenaflerone hourincubation.
F1+2concentrationwasone-fifththatgeneratedmnormalprothrombin(@j. 3c). Veryslowactivation
of prothrombrnSegoviawasobservedm SDS-PAGE,becausewhiletheformationof thrombinwas
clearlyappreciatedm normalprothrombin,it was not observedin prothrombrnSegovia.After
reduction,the intermediatefi-agmentsof normalprothrombinactivationproducedB chain,whilem
prothrombinSegoviatherewas a decreasem the rntensityof transito~products,withoutB chain





prothrombin.Thiscanbe explainedbecausewhiletheactionon substrateS-2238isproducedby active
intermediates(MT andMT-desF1)(33) aswellasthrombrn,theclottingactivityis onlygeneratedby
thrombin(13). Moreover,thegreatresistanceof prothrombinSegoti to reductionof intermediates,
porntsto anaccumulationof intermediateslackinga cleavedbondB (Arg320-lle321),andtherefore,
not expressingthe activesite.However,the clottingactivityandthe formationof the 57000 Da




Polyacrilamideg lelectrophoresisnthepresenceof sodiumdodecjl sulfite(SDS-PAGE)of
purifiedandprothrombinSegovia.






























(PN) by prothrombrnasecomplexm thepresence(blackline)andabsence(stripedline)of
fiwtorV. A) Clottingactivity;B) amidolyticactivity.
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FragmentF1+2 concentrationgenerated uringactivationof prothrombinSegovia(st@ed
line)andnormalprothrombin(blackline)by: A) prothronibinasecomplex;B) Taipansnake
venomandC)Echiscarinutusvenom.
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Upon atiation by Taipansoakevenoq prothrombrnSegoviareacheda plateauof clottingand
amidolyticactivitiesatthesametime,thusdemonstratingthatthrombinistheonlyactiveenzyme(35)
andthattheactivationpathwayis throughP2 (36). Similarto prothrombinasecomple~resistanceto
reductionisreflectedby theaccumulationof P2.Nevertheless,theclottingactivityandtheproduction


























Cleavagepatternsof normalprothrombin(PN) andprothrombinSegovia(PS) by Echis
carinatusvenomunderA) nonreducedandB) reducedconditions.Lanesa to d inPN and
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FIG 6
Westernblotunderreducedconditionsof cleavagepatternsof A) normalandB) prothrombin
SegoviabyEchiscarinatmvenom,Lanesato e: time5, 30, 180, 480 minutesand24 hours.
P,prothrombrn;MT, meizothrombrn;Pl, prethrombin1;MT-desFl,meiz.othrombin-desFl;
P2,prethrombrn2; T, thrombin;Fl, fragment1.
SDS-PAGE analysisinsinuatedsomedegreeof activatio~shownby the parallelismbetweenthe
increaseinthe57000Daintermediateintensityandthedecreasemthe72000Daintermediaterntensity,
whichsuggeststhattheformeris formedfromthelatter.Thisactivationwas alsoconfirmedby the
appearanceofthrombrnintheWeStemblot,andbythegenerationof F1+2.
Up untilnow, theknowndysprothrombinemiashavebeencharacterizedby defectsm thefollowing
sites:a) scissionof bondA; b) fragment1;c) thrombrnpartof themolecule(dysthrombinemia);ndd)
scissionof bondB. Theformationof P2,thrombrnandF1+2withprothrombinasecomplexandTaipan
snakeveno~ suggeststhatscissionof bond~ Arg271-Thr272m prothrombinSegoviais normal.
Moreover,mprothrombrnsBarcelona(39)andMadrid(40),whicharecharacterizedbythisdefect,the
activationwithEchiscarinatusvenomwasnom@ m contrasto prothrombrnSegovia.We canalso
discardanabnormahtym fragmentF1 likethatof prothrombinSanJuan(41), becauseprothrombin
Segoviais quantitativelyadsorvedinbariumsaltanditsimmunoelectrophoreticpatterninthepresence
of calciumisnormal.
There are some similmt“ies between prothrombinSegovia and some well recognized
dysthrombinemias,i.e., a decreaseof clotting and amidolyticactivitiesafier activationwith
prothrombrnasecomple< similarto prothrombrnsMolise(42), Quick(43), Metz (44), Tokushima
(45), Salakta(46),Habana(14) andHimi(7). However,mthesedysthrombrnemias,thedecreasewith
prothrombinasecomplexandTaipansnakevenomwasmoredrasticthatmprothrombinSegovia.On
theotherhand,thebehaviourof intermediatesof prothrombinSegoviaatlerreductionwas dit%rent
thanthatfoundm dysthrombinemiaswhereB chainwas produced.In prothrombinHimi(7), tier
activationwithEchiscarinatu.svenoq the cleavagepatternwasnom@ whichis very difkrentto
prothrombrnSegovia.We cannotdiscardadefectmthethrombinpartof prothrombinSegovia;sucha
defect,wouldexplainthe delaym its acttiationwithprothrombinasecomplexandEchiscarinatus
venom.
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An alterationm the scissionof bond B, was firstpostulatedby Rocha et al (1986) who founda
distinctivepatternof peaksmbidimensionale etrophoresis(l), generallyrelatedwitha defectm the
activationprocess(2, 12).
Theonlydysprothrombinemiawhereanalteredcleavageof bondB, probablyrnducedby anafEnity
impairmentof fimtorXa to prothrombin(47),hasbeenfoun~ isprothrombrnClamartwhichhasthe
followingcharacteristics:thethrombiugenerationrateby prothrombinasecomplexistwiceasslowas
thatof normalprothrombinand SDS-PAGEanalysisof the finalactivationproductsrevealsan
abnormalaccumulationof P2, resistanto reductio~witha lesserdegreeof thrombinformation.
SimilaresultswerefoundmprothrombinSegoviawiththeprothrombinasecomplexandtheTaipan
snakevenom.ThedefectinprothrombinClamartliesmthescissionof bondB, Arg320-Ile321.
The lesserdegreeof amidolyticthanclottingactivityobservedm prothrombrnSegoviaand the
accumulationof Arg320-lle321intermediatesnot cleavedwiththeprothrombrnasecomple~ suggest
fewerintermediateswithanuncoveredactivesite.ThemoreevidentresultwasproducedwithEchis
carinatusveno~ whichactssolelyon bondB (48), becausewhenitwasusedas atiator, thrombin
formationwaspracticallyabsentandtier thereductionof activationintermediates,theB chaindidnot
appearintheSDS-PAGEanalysis.Nevertheless,theproductionof clottingandamidolyticactivitiesas
wellasautolysisreactions(49), suggestsa smallcleavageof thisbond.
In orderto studyf%ctorVa influence, prothrombinSegoviawas activatedwithprothrombrnase
complexintheabsenceof fictor V. Ve~ poor or no thrombrngenerationwas foundby amidolytic
activityorby clottingactivity,respectively.SeveralstudieshaveshownthatfactorVanotonlybrndsto
thesubstrate,prothrombiqbutalsomodulatestheconiiormationof itsproteasedorm@ determinhg
theproteolysisefficiencyof fktor Xa (50, 51, 52, 53). Sincefictor Va produceda moderatelyactive
thrombinmoleculefromprothrombinSegovia,itispossiblethatfactorVamadethescissionof bondB
easier,probablybyrnducingamoreappropriateconilormationof prothrombiu.
Ourresultssoggestthatthe defectof prothrombinSegoviaimpairsthe correctscissionof bondB,
Arg320-lle321,althoughitisunlikelythatitislocatedmoneoftheseamino-acids.
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